American Society of Addiciton Medicine

Home Publications The ASAM Weekly The ASAM Weekly Newsletter

The ASAM Weekly for September 15, 2026

Sep 16, 2026, 11:40 by ASAM Weekly Editors
Stimulant-only overdose deaths rising amid opioid decline, care navigation for methamphetamine use disorder, cannabis detected in 21% of overdose deaths, prescription cannabis use disorder, adolescent polysubstance co-use and dosing, Addiction Consult Services reducing readmissions, prenatal alcohol exposure and brain maturation, and youth substance use ED visits.
ASAM Weekly — September 16

Non-Opioid Overdose & Emerging Trends

Last week, I opened with the encouraging news that overdose deaths are plateauing, citing opioid studies. This week, our focus shifts to non-opioid substances and polysubstance overdose.

Unfortunately, US drug overdose deaths involving stimulants without opioids continued to rise in 2024. I love to plug the ASAM/AAAP guidelines for treating stimulant use disorder; complementing this guidance, a new JAMA Network Open RCT investigates the efficacy of care navigation for methamphetamine use disorder. Interestingly, another substance, cannabis, is reported by the CDC to be detected in 1 out of 5 overdose deaths, especially among youth, underscoring treatment of cannabis use disorder as a good avenue for early intervention. (We also touch on “medical cannabis” this week.)

Youth & Developmental Research

On the theme of youth, recent studies highlight critical vulnerabilities across development:

Implementation & Purpose in Addiction Medicine

As an addiction community, we know these associations exist; this week’s issue strengthens that conviction and calls us to action. Proven interventions such as Addiction Consult Services consistently improve outcomes. As part of the workforce implementing these essential changes, we impact everything from acute overdose to youth health.

Given how painful the intersection of youth and overdose is, I close with an uplifting piece from MedPage Today on why Dolly Parton is an excellent role model for doctors, reminding us of the power of authenticity and empathy. As Dolly famously put it: “Find out who you are and do it on purpose.”

Smita Das, MD, PhD, MPH
Editor in Chief

with Co-Editors: Brandon Aden, MD, MPH, FASAM; John A. Fromson, MD; Sarah Messmer, MD, FASAM; Jack Woodside, MD; and Contributing Editor: Jessica Gregg, MD, PhD, FASAM

The National Institute on Drug Abuse (NIDA) has issued a Request for Information (RFI) inviting feedback on the 2027-2031 NIDA Strategic Plan.

To view the RFI and submit feedback, please see: NOT-DA-26-014: Request for Information: Inviting Input on NIDA’s Strategic Plan for 2027–2031

To ensure consideration, responses must be submitted by:
September 21, 2026, 11:59:59 PM EST

Lead Story

US drug overdose deaths involving stimulants without opioids continued to rise in 2024 🔓
Addictive Behaviors Reports
Drug overdose deaths (DOD) peaked in 2022 before a decline in rates driven by a decrease in opioid-related deaths. We are now in the “fourth wave” of the overdose epidemic, represented by DOD involving polysubstance use. As the decline in DOD has been driven largely by the decline in deaths related to fentanyl, researchers sought to assess if DOD due to stimulants alone (without opioids) were also in decline. Researchers found that DOD rates related to cocaine without opioids (1.7% increase) and methamphetamines without opioids (2.4% increase) remained stable or increased between 2023 and 2024. Notably there was some regional variation with the greatest increase in DOD rates seen in the Northeast (3.7% for cocaine and 26.7% for methamphetamines). The authors note that stimulant-specific interventions may be needed to address the ongoing DOD epidemic.

ASAM Publications Council Call for Applications

ASAM is seeking up to 3 members to serve on the Publications Council beginning in January 2027. Council members should have experience in addiction medicine and familiarity with the writing and publishing process. The Publications Council is charged with overseeing ASAM publications. The Council approves publication editors, evaluates proposals for new publications, ensures adequate publisher performance, and regularly furnishes the Board of Directors with updates on publication activities.

Please first log into your ASAM member portal and click to apply.
The closing date is September 21, 2026.

Research and Science

Care navigation for methamphetamine use disorder: A randomized clinical trial 🔓
JAMA Network Open
This is a prospective randomized clinical trial of a care navigation intervention including contingency management compared to usual care in Denver, Colorado, from April 2023 to December 2024. The primary study outcome was linkage to treatment within 30 and 90 days of enrollment. The navigation intervention was client driven and trauma informed, and included navigation support for communication, transportation, disability, food and clothing assistance, housing, SUD treatment, other health care, and employment. Navigators attempted to meet with participants weekly, and participants could earn incentives for these meetings for up to 12 weeks. A total of 192 participants were enrolled (96 randomized to each arm), with a median age of 39; 85% were unstably housed, and 67% reported a prior diagnosis of a mental health disorder. Of those in the intervention arm, 63% engaged in 2 or more navigation sessions, with a median of 5 sessions received. Despite this engagement with the care navigator in the intervention arm, there was no significant difference in linkage to treatment at 30 or 90 days between groups.
Notes from the field: Cannabis detection among overdose deaths — United States, 2021–2025 🔓
Morbidity and Mortality Weekly Report
Data were obtained from CDC’s State Unintentional Drug Overdose Reporting System (SUDORS) for 209,166 overdose deaths between 2021 and 2025. Cannabis was detected in 21% of deaths (which was stable over time) and was listed as involved in causing death in 0.8%. Only 9 deaths had no other drug detected indicating cannabis-caused deaths are rare. Cannabis was detected most often in those aged 11–17 years (43%) and least often in those aged >50 years (17%). Since cannabis is not routinely tested for in overdose deaths, these figures are likely underestimates. Cannabis use among youths presents an opportunity for early intervention to prevent cannabis use disorder and other substance use.
Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition? 🔓
Addiction
This study compared the 12-month prevalence rates of cannabis use disorders (CUD) in a sample of people prescribed medical cannabis in Australia by a medical or nurse practitioner, according to whether they use conventional DSM-5 11-items for CUD versus 9-items for prescription cannabis use disorder (Pr-CUD). Researchers found that DSM-5 CUD diagnostic criteria developed for illicit cannabis use may not be appropriate for people using medical cannabis under prescribed conditions. CUD rates are statistically significantly reduced when the Pr-CUD framework is applied to people only using cannabis products in accordance with the conditions identified on their prescription (including dose, route of administration, and indication). This has considerable clinical and policy implications in settings where medical cannabis is legally available under a prescription model.
Co-use of some substances associated with higher doses in adolescents: Findings from the Adolescent Brain Cognitive Development Study 🔓
Journal of Adolescent Health
Nicotine, alcohol, and cannabis are the most commonly used substances among adolescents. Their use often co-occurs. Using data from 6 waves of the Adolescent Brain Cognitive Development Study, the patterns and doses of substance co-use in this vulnerable population were assessed. The average dose of nicotine was significantly higher when co-used with alcohol or when co-used with cannabis in year 6; nicotine trends were similar in years 4 and 5. In year 6, the average dose of alcohol was higher when co-used with cannabis or co-used with nicotine compared to single use of alcohol. The average dose of cannabis was not significantly different when used singularly or co-used with either alcohol or nicotine in the study years examined.
Impact of Addiction Consult Service on alcohol use disorder medications and postdischarge outcomes 🔓
Journal of Addiction Medicine
This retrospective cohort study evaluated the impact of a multidisciplinary Addiction Consult Service (ACS) at Vanderbilt University Medical Center from 2018 to 2025 on inpatient initiation of medications for alcohol use disorder (MAUD); MAUD prescribed at discharge; and 30-day readmission, ED presentation, or death. A total of 4,428 admissions were included in the analysis (2,214 received ACS, 2,214 were propensity matched with no ACS). ACS consultation was associated with a 32.8% higher rate of MAUD initiation while inpatient, a 7.4% higher rate of MAUD prescriptions at discharge, and a 5% reduction in 30-day readmission, ED presentation, or death as compared to usual care.

Learn More

Early adversity, lasting impact: Characterizing cortical morphology in youth with prenatal alcohol exposure 🔓
Drug and Alcohol Dependence
These researchers studied the relationship between brain anatomy and prenatal alcohol exposure (PAE). Participants aged 7–21 years received brain MRI scans. Of 123 total participants, 58 had PAE (>7 drinks/week or >2 binges/pregnancy), and of these 31 had diagnosed fetal alcohol spectrum disorder. Local gyrification index (LGI) reflects the amount of cortex in the sulcus. LGI decreased with age in 2 brain regions in PAE but increased in unexposed controls. LGI increased with age in one brain region with PAE but was unchanged in unexposed controls. With PAE, sulcal depth was decreased in one brain region compared to controls. Of interest, PAE had no effect on cortical thickness. Lower gyrification is associated with lower intelligence. Sulcal depth is a sensitive marker for cortical abnormalities and is seen in major depression, Parkinson’s, and Alzheimer’s. The authors conclude that brain maturation is disrupted by PAE.
Substance use emergency department visits among young people: Exploring individual and contextual risk factors 🔓
Journal of Community Psychology
Individual- and community-level factors have been associated with patterns of substance use, and to better understand them and their potential interaction researchers looked at substance use-related emergency department (ED) visits among youth in North Carolina. Individual-level variables included income, age, race, and sex, while at the community level researchers primarily examined income status. At the individual level, factors associated with increased likelihood of ED visit for substance use were being male, being White, and being low-income. At the community level, being from a high-income area was associated with increased likelihood of alcohol- and opioid-related ED visit. However, researchers found significant interaction between community- and individual-level factors such that Black and Hispanic youth from low-income communities were particularly at risk.

In the News

The ASAM Weekly

Editors & Staff

Editor-in-Chief: Smita Das, MD, PhD, MPH
Emeritus Editor: William Haning, MD, DFAPA, DFASAM, Nicholas Athanasiou, MD, MBA, DFASAM
Publications Chair: Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors: Brandon Aden, MD, John A. Fromson, MD, Sarah Messmer, MD, Jack Woodside, MD
Contributing Editor: Jessica Gregg, MD, PhD, FASAM

Please direct customer service inquiries and comments to: ASAMWeekly@ASAM.org

The ASAM Weekly

Advertiser Services & Sales

Ad space is limited and available on a first-paid, first-published basis. To assure your ad will run in the specific issue you select, Insertion Orders must be signed by an authorized person in your organization and accepted by your customer service representative before taking the advertising units out of the active sales inventory. Payment must be received prior to the run date for an ad. Insertion Orders provide several options for payment in full including all major credit cards or check. Pre-approved billing must be arranged directly by an ASAM representative.

To learn more about advertising opportunities
Contact: Claire Rasmussen <crasmussen@asam.org>